health economics

Pharma Faces Longer Approval Times, Lower Reimbursement Rates in Years Ahead—Effective Payer KOLs the Answer

Pharmaceutical manufacturers will face longer regulatory approval times and lower reimbursement rates in the years ahead according to new IMS data. A recent IMS release summarizes market forecasting data, including reduced drug spending by public payers and more extensive reviews of new therapies. To navigate effectively through these new challenges, pharmaceutical companies will need a …

Pharma Faces Longer Approval Times, Lower Reimbursement Rates in Years Ahead—Effective Payer KOLs the Answer Read More »